Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trabectedin 4Doxorubicin 4toripalimab 2brigimadlin 2belinostat 2Fulvestrant 2Dexamethasone 2tanespimycin 1soblidotin 1siremadlin 1selinexor 1ridaforolimus 1ribociclib 1pembrolizumab 1olaratumab 1milademetan 1enzalutamide 1cemiplimab 1atezolizumab 1TTI-621 1Sugars 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Midazolam 1Letrozole 1Injections 1Immunotherapy 1Imatinib Mesylate 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Liposarcoma × soblidotin × Clear all
NCT00064220 2012-05-16

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Daiichi Sankyo

Phase 2 Completed
Sarcoma

Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡